Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum
Rhea-AI Summary
Rapid Micro Biosystems (Nasdaq: RPID) will participate in the KeyBanc Capital Markets Healthcare Forum with a virtual Q&A on March 17, 2026 at 11:15 a.m. ET. A live webcast will be available on the company's investor relations site and will be archived for later replay.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – RPID
On the day this news was published, RPID gained 6.05%, reflecting a notable positive market reaction. Argus tracked a peak move of +10.9% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $11M to the company's valuation, bringing the market cap to $198.12M at that time. Trading volume was elevated at 2.2x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows peers like RCEL and ARAY moving up, but sector_momentum is flagged as company-specific and the target’s direction is unspecified, indicating this headline is not part of a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Conference participation | Neutral | -3.1% | Announcement of TD Cowen healthcare conference presentation and webcast details. |
| Feb 24 | Earnings timing | Neutral | +6.3% | Scheduling of Q4 and full-year 2025 results release and webcast. |
| Feb 12 | Equity inducement | Neutral | +2.8% | Inducement RSUs and options granted to new employees under Nasdaq rules. |
| Jan 13 | Prelim revenue | Positive | +21.1% | Record preliminary unaudited Q4 and 2025 revenue and system placements. |
| Jan 07 | Conference participation | Neutral | -1.2% | Notice of J.P. Morgan Healthcare Conference presentation and webcast. |
Recent RPID news has included multiple conference appearances and one strong preliminary revenue update. Price reactions have ranged from modest moves around conference and administrative updates to a sharp 21.05% gain on record preliminary 2025 revenue, suggesting investors respond most strongly to concrete financial performance disclosures.
Over the last few months, Rapid Micro Biosystems has issued a mix of conference participation notices, administrative updates, and a key preliminary revenue release. The company reported record unaudited Q4 and full‑year 2025 revenue on Jan 13, 2026, which saw the stock rise 21.05%. Other items, such as inducement grants and conference/webcast announcements, produced smaller price moves in both directions. Today’s KeyBanc forum participation fits the pattern of communication-focused updates rather than a new financial or clinical catalyst.
Market Pulse Summary
The stock moved +6.0% in the session following this news. A strong positive reaction aligns with the stock’s history of responding most to concrete fundamentals, such as the 21.05% move after record preliminary 2025 revenue on Jan 13, 2026. This announcement is a communication-focused event, similar to prior conference notices. Sustainability of any sharp gain would likely depend on upcoming catalysts like the scheduled March 12, 2026 earnings release and subsequent execution updates.
Key Terms
webcast technical
AI-generated analysis. Not financial advice.
LEXINGTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the KeyBanc Capital Markets Healthcare Forum.
The Company is scheduled to participate in a virtual question and answer session with the host analyst on Tuesday, March 17, 2026, at 11:15 a.m. Eastern Time. A live webcast will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts, and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications mbeaulieu@rapidmicrobio.com Media Contact: media@rapidmicrobio.com